Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

siltuximab

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

- PMLiVE

EMA offers orphan drug benefits for Ebola research

Incentives to encourage development of new treatments for the virus

- PMLiVE

Janssen’s blood cancer drug Imbruvica approved in Europe

European commission licenses the first-in-class drug for two rare diseases

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

EU flag

Germany, UK and Denmark lead mental health integration

But Janssen-backed report says progress is still needed in Europe

- PMLiVE

IPHA names Janssen’s Dr Leisha Daly as president

Has been vice president since 2012

- PMLiVE

Novartis’ Bexsero triumphs at UK Prix Galien

The Awards also saw Janssen's Sirturo pick up the Orphan Drug prize

- PMLiVE

Janssen backs NHS diabetes challenge

Will provide £200,000 to spread innovation across UK

- PMLiVE

FDA awards $19m in rare disease grants

US regulator supports 15 orphan drug projects

- PMLiVE

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links